We are developing a new kit for prediction of Multiple sclerosis (MS) patient’s response to either IFN-β treatment or Copaxone treatment based on their PGE (personal genes expression).
We focused on two types of MS: Remitting relapsing (RR) or Secondary progressive (SP). The PGE signature from blood samples for MS is significant and enable to distinguish between Responders and Non-responders.
First clinical trial is on going in Shaare Zedek medical center in Jerusalem.
The graph below represents 15 patients(X axis) and their PGE level (Y axis). The Blue bars- PGE level before treatment and Red bard- PGE level 24 hours after IFN-β treatment. There is a clear increase in the PGE level of the Responders 24 hours after the treatment.
We have obtained a second significant and specific PGE for Copaxone treatment as well. This PGE is currently being verified in clinical tests.Tags: Copaxone, IFN-β